Health
Single Dose of Johnson & Johnson COVID-19 Vaccine Candidate Demonstrates Robust Protection in Pre-clinical Studies – PRNewswire
/PRNewswire/ — Johnson & Johnson (NYSE: JNJ) (the Company) today announced that its lead vaccine candidate protected against infection with SARS-CoV-2, the…
NEW BRUNSWICK, N.J., July 30, 2020 /PRNewswire/ — Johnson & Johnson (NYSE: JNJ) (the Company) today announced that its lead vaccine candidate protected against infection with SARS-CoV-2, the virus that causes COVID-19, in pre-clinical studies. The data, published in Nature, show the Company’s investigational adenovirus serotype 26 (Ad26) vector-based vaccine elicited a robust immune response as demonstrated by “neutralizing antibodies,” successfully preventing subsequent infection and provi…
-
Noosa News13 hours agoChild, 15, arrested over death of another child, 8, after shocking e-bike crash in Queensland
-
General11 hours agoCrowe toasts talkback titan for platforming ‘voiceless’
-
Noosa News12 hours agoLyka Doggie Date Night at Moonlight Cinema
-
Noosa News12 hours agoQueensland Drug and Alcohol Court provides sentencing options – Proctor